Results 101 to 110 of about 19,315 (197)

Ticagrelor Exerts Immune-Modulatory Effect by Attenuating Neutrophil Extracellular Traps

, 2020
Neutrophils through the release of neutrophil extracellular traps (NETs) containing active tissue factor (TF) are key components of thrombo-inflammation. Platelets-neutrophils interplay in ST elevation myocardial infarction (STEMI) promotes NET formation
Iliana Angelidou, Alexandros Mitsios, Akrivi Chrysanthopoulou, Veroniki Vidali, Dimitrios Stakos, Athanasios Arampatzioglou, Konstantinos Ritis, Panagiotis Skendros   +7 more
core   +1 more source

PEMBENTUKAN MULTIKOMPONEN KRISTAL TICAGRELOR-MEGLUMIN DAN KARAKTERISASI SIFAT FISIKOKIMIA

, 2023
Ticagrelor merupakan obat antiplatelet yang tergolong ke dalam kelas 4 dalam Sistem Klasifikasi Biofarmasi yang memiliki kelarutan dan permeabilitas rendah.
Ahdi, Dinil Haq. AH
core  

TICAGRELOR : ANTAGONIS P2Y 12

, 2013
Golongan antagonis P2Y 12 merupakan salah satu pilihan terapi kombinasi antiplatelet bersama dengan aspirin untuk pasien dengan sindrom koroner akut baik NSTEMI (non-ST elevation myocardial infarction) maupun STEMI (ST elevation myocardial ...
Presley, Bobby
core  

Comparison of Ticagrelor with Clopidogrel in Reducing Interleukin-17 and Myeloperoxidase Expression in Thrombus and Improving Postprocedural Coronary Flow in ST-segment Elevation Myocardial Infarction Patients

Journal of Pharmacy & Pharmaceutical Sciences, 2018
Purpose. This study aimed to explore the effects of ticagrelor (a P2Y12 receptor inhibitor) on interleukin (IL)-17 and myeloperoxidase (MPO) expression in coronary thrombus as well as on the coronary blood flow in ST-segment elevation myocardial ...
WenHua Li, SongQi Guo, Shu Wang, Xin Sun, ZhuQin Li, XinYong Sun, YanMing Sun, LanFeng Wang, Wei Pan   +8 more
doaj   +1 more source

Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.

, 2016
OBJECTIVE The effects of ticagrelor in the subpopulation of patients with ST-elevation myocardial infarction (STEMI) were consistent with those observed in the overall Platelet Inhibition and Patient Outcomes (PLATO) study.
Meier, Bernhard,, Velders, Matthijs A, Harrington, Robert A.,, Angiolillo, Dominick J.,, Katus, Hugo A.,, Ardissino, Diego, Himmelmann, Anders,, Abtan, Jérémie, Harrington, Robert A, Wallentin, Lars, Husted, Steen, Husted, Steen,, Himmelmann, Anders, Katus, Hugo A, Angiolillo, Dominick J, Meier, Bernhard, Storey, Robert F, James, Stefan K.,, Velders, Matthijs A.,, Steg, Philippe Gabriel,, James, Stefan K, Hellkamp, Anne,, Schulte, Phillip J, Storey, Robert F.,, Abtan, Jeremie,, Wallentin, Lars,, Schulte, Phillip J.,, Ardissino, Diego,, Gabriel Steg, Philippe, Hellkamp, Anne   +29 more
core   +1 more source

Ticagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosis [PDF]

, 2015
In the PLATO study, ticagrelor was associated with fewer pulmonary infections and subsequent deaths than clopidogrel. Neutrophils are a first-line defence against bacterial lung infection; ticagrelor inhibits cellular uptake of adenosine, a known ...
Thomas, Mark R., Lynne R. Prince, Haroon Khan, Khan, Haroon, Prince, Lynne R., Sabroe, I., Khalaf F. Alsharif, Ridger, V.C., Victoria C. Ridger, Alsharif, Khalaf F, Prince, L.R., Mark R. Thomas, Thomas, M.R., Judge, H.M., Prince, Lynne R, Storey, Robert F, Robert F. Storey, Alsharif, K.F., Storey, R.F., Alsharif, Khalaf F., Storey, Robert F., Judge, Heather M., Judge, Heather M, Khan, H., Ian Sabroe, Ridger, Victoria C., Sabroe, Ian, Heather M. Judge, Thomas, Mark R; id_orcid, Ridger, Victoria C   +29 more
core   +1 more source

Ticagrelor in ST-Elevation Myocardial Infarction

, 2012
Ticagrelor is a new oral antagonist of the platelet P2Y12 receptor that offers several potential advantages compared to clopidogrel including faster and more effective inhibition of platelet aggregation. Ticagrelor has been compared to clopidogrel in the
Niccoli, Giampaolo
core   +2 more sources

Ticagrelor versus clopidogrel in the management of acute myocardial infarction

Journal of Community Hospital Internal Medicine Perspectives, 2019
Hypothesis: In the care of acute myocardial infarction, ticagrelor attenuates post-ischemic myocardial damage and inhibits platelet activity to a greater extent than clopidogrel.
Candice Volney, Anthony Collins, Sarah Adams   +2 more
doaj   +1 more source

Ticagrelor induces adenosine triphosphate release from human red blood cells

, 2012
RATIONALE: The novel P2Y(12) antagonist ticagrelor inhibits ADP-induced platelet aggregation more rapidly and more potently than clopidogrel. Clinical trials have revealed dyspnea and asymptomatic ventricular pauses as side effects of ticagrelor.
Erlinge, David,, Albinsson, Sebastian,, Kudira, Ramesh,, Öhman, Jenny,, Olde, Björn,, Lund University.   +5 more
core   +1 more source

Ticagrelor, a platelet aggregation inhibitor for the potential prevention\ud and treatment of arterial thrombosis and acute coronary syndromes

, 2009
Ticagrelor is an orally active ADP P2Y12 receptor antagonist in development by AstraZeneca plc for the reduction of recurrent ischemic events in patients with acute coronary syndromes (ACS).
Doggrell, Sheila
core